Stock listing
Aquis:PHME Pharma Mar SA Share Price
UK listing (Aquis) of Pharma Mar SA · home listing BME:PHM
Follow Pharma Mar SA into a list and get an email when it puts out news.
Home listing price · BME:PHM
€57.80 EUR -4.25 (-6.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, BME:PHM
- Day range
- €57.15 – €58.60 EURNov 20, 2026
- Volume
- 99,554 sharesNov 20, 2026
- Market cap
- €997.8M EURAt the close on Nov 20, 2026 · price × 17.26M shares outstanding
- 52-week range
- €57.15 – €105.20 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €2.47M EURMedian day 27,630 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| BME:PHM · Home | €57.80 EUR | -4.25 (-6.8%) | 99,554 | €58.60 | €58.60 | €57.15 | €62.05 | Close on Nov 20, 2026 |
| OTC:PHMMF | $66.95 USD | -5.592 (-7.7%) | 100 | $66.95 | $66.95 | $66.95 | $72.54 | Close on Nov 18, 2026 |
| Frankfurt:PMRA | €58.35 EUR | -3.85 (-6.2%) | — | €58.35 | €58.35 | €58.35 | €62.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · BME:PHM · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €57.80 | -4.25 | -6.8% | €58.60 | €58.60 | €57.15 | 99,554 | |
| €62.05 | -2.20 | -3.4% | €64.60 | €64.70 | €62.05 | 59,402 | |
| €64.25 | -2.35 | -3.5% | €66.00 | €66.00 | €64.15 | 43,553 | |
| €66.60 | -0.65 | -1.0% | €67.25 | €67.85 | €66.40 | 13,579 | |
| €67.25 | -1.10 | -1.6% | €68.00 | €68.75 | €66.85 | 20,216 | |
| €68.35 | -0.95 | -1.4% | €69.95 | €70.05 | €67.85 | 37,602 | |
| €69.30 | +0.30 | +0.4% | €69.70 | €69.90 | €68.75 | 26,260 | |
| €69.00 | +1.60 | +2.4% | €67.45 | €69.70 | €67.45 | 45,075 | |
| €67.40 | +2.00 | +3.1% | €65.60 | €67.40 | €65.60 | 37,068 | |
| €65.40 | -0.50 | -0.8% | €65.15 | €66.20 | €64.15 | 39,477 | |
| €65.90 | -0.95 | -1.4% | €67.60 | €67.80 | €65.65 | 47,527 | |
| €66.85 | +2.60 | +4.0% | €65.05 | €67.25 | €64.60 | 63,765 | |
| €64.25 | -1.60 | -2.4% | €65.20 | €65.70 | €62.00 | 123,853 | |
| €65.85 | -1.65 | -2.4% | €67.25 | €67.40 | €65.20 | 57,802 | |
| €67.50 | -1.75 | -2.5% | €68.90 | €69.35 | €66.00 | 72,911 | |
| €69.25 | +0.65 | +0.9% | €69.00 | €70.90 | €68.35 | 49,058 | |
| €68.60 | -0.50 | -0.7% | €69.75 | €70.35 | €68.60 | 26,155 | |
| €69.10 | +1.05 | +1.5% | €68.40 | €70.05 | €67.95 | 25,414 | |
| €68.05 | -1.20 | -1.7% | €68.95 | €70.25 | €68.00 | 31,040 | |
| €69.25 | -1.45 | -2.1% | €70.70 | €71.00 | €69.05 | 16,899 | |
| €70.70 | -0.10 | -0.1% | €70.50 | €71.15 | €70.20 | 18,123 | |
| €70.80 | +1.55 | +2.2% | €69.50 | €70.90 | €69.00 | 28,048 | |
| €69.25 | +0.80 | +1.2% | €67.95 | €70.05 | €67.70 | 23,081 | |
| €68.45 | +0.55 | +0.8% | €67.50 | €68.45 | €67.20 | 26,204 | |
| €67.90 | -0.50 | -0.7% | €68.40 | €69.60 | €67.90 | 28,402 | |
| €68.40 | +1.10 | +1.6% | €67.45 | €68.85 | €66.70 | 33,621 | |
| €67.30 | +0.85 | +1.3% | €66.80 | €67.90 | €66.35 | 33,156 | |
| €66.45 | -1.80 | -2.6% | €68.00 | €69.20 | €66.45 | 34,695 | |
| €68.25 | -1.20 | -1.7% | €69.75 | €70.15 | €68.25 | 16,715 | |
| €69.45 | +0.85 | +1.2% | €68.60 | €69.85 | €68.35 | 23,960 | |
| €68.60 | -1.15 | -1.6% | €69.55 | €69.55 | €68.05 | 32,846 | |
| €69.75 | -0.55 | -0.8% | €69.70 | €70.75 | €69.70 | 14,861 | |
| €70.30 | +0.65 | +0.9% | €70.45 | €71.50 | €69.65 | 21,642 | |
| €69.65 | -1.75 | -2.5% | €71.30 | €71.55 | €69.50 | 30,249 | |
| €71.40 | +0.65 | +0.9% | €70.50 | €71.65 | €69.60 | 27,211 | |
| €70.75 | -2.35 | -3.2% | €72.45 | €73.05 | €70.75 | 47,245 | |
| €73.10 | +0.70 | +1.0% | €72.90 | €73.30 | €72.10 | 23,783 | |
| €72.40 | -1.50 | -2.0% | €74.00 | €74.10 | €72.35 | 19,746 | |
| €73.90 | -0.05 | -0.1% | €74.05 | €74.50 | €73.15 | 15,001 | |
| €73.95 | +0.45 | +0.6% | €73.50 | €74.90 | €73.50 | 21,369 | |
| €73.50 | +0.65 | +0.9% | €72.85 | €74.30 | €72.20 | 23,497 | |
| €72.85 | -1.80 | -2.4% | €75.30 | €75.50 | €72.85 | 23,312 | |
| €74.65 | +0.70 | +0.9% | €74.20 | €75.05 | €74.00 | 26,275 | |
| €73.95 | +0.30 | +0.4% | €73.75 | €74.40 | €72.80 | 20,985 | |
| €73.65 | -1.35 | -1.8% | €75.95 | €75.95 | €73.05 | 44,400 | |
| €75.00 | -1.25 | -1.6% | €76.25 | €76.70 | €75.00 | 54,453 | |
| €76.25 | +0.10 | +0.1% | €77.00 | €77.00 | €75.95 | 12,847 | |
| €76.15 | -0.30 | -0.4% | €76.00 | €76.95 | €75.75 | 15,642 | |
| €76.45 | -0.05 | -0.1% | €75.50 | €76.80 | €75.50 | 29,506 | |
| €76.50 | -0.45 | -0.6% | €77.25 | €77.25 | €75.85 | 23,995 | |
| €76.95 | -1.70 | -2.2% | €78.65 | €79.05 | €76.10 | 42,350 | |
| €78.65 | -1.35 | -1.7% | €80.00 | €80.00 | €77.80 | 57,503 | |
| €80.00 | -2.20 | -2.7% | €82.30 | €82.85 | €76.90 | 95,703 | |
| €82.20 | -1.25 | -1.5% | €84.00 | €84.00 | €82.20 | 11,728 | |
| €83.45 | -0.30 | -0.4% | €83.70 | €84.00 | €82.60 | 18,110 | |
| €83.75 | +1.00 | +1.2% | €83.00 | €84.50 | €82.85 | 20,611 | |
| €82.75 | +0.05 | +0.1% | €82.20 | €84.10 | €82.15 | 26,527 | |
| €82.70 | +1.35 | +1.7% | €81.65 | €83.50 | €80.85 | 24,428 | |
| €81.35 | -1.45 | -1.8% | €82.70 | €82.80 | €81.30 | 45,068 | |
| €82.80 | -0.80 | -1.0% | €83.65 | €84.30 | €82.80 | 16,313 | |
| €83.60 | 0.00 | 0.0% | €84.30 | €84.90 | €83.60 | 18,853 | |
| €83.60 | -0.25 | -0.3% | €83.50 | €85.10 | €83.50 | 29,225 | |
| €83.85 | +1.55 | +1.9% | €82.80 | €84.40 | €82.50 | 29,695 | |
| €82.30 | -1.00 | -1.2% | €82.95 | €83.00 | €80.90 | 26,264 | |
| €83.30 | +1.15 | +1.4% | €82.20 | €83.35 | €80.80 | 45,400 | |
| €82.15 | +0.05 | +0.1% | €82.65 | €84.40 | €81.50 | 40,746 |
Splits
6 splits since 1999 · BME:PHM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 51-for-50 | Split | |
| 5-for-4 | Split | |
| 4-for-1 | Split | |
| 3-for-1 | Split | |
| 5-for-1 | Split |
- Ticker
- Aquis:PHME
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Aquis
- Currency
- EUR
What changed lately
Latest news release · Mar 13, 2026
Pharma Mar: Consolidated Financial Statements and Consolidated Directors' Report (Consolidated Financial Statements and Consolidated Directors)
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 25 slides
Latest news
Pharma Mar: Consolidated Financial Statements and Consolidated Directors' Report (Consolidated Financial Statements and Consolidated Directors)
Mar 13, 2026
Closed €78.75 (-0.6%) on Mar 13, 2026
Press Release (PR PhM Results FY2025 final 1)
Feb 27, 2026
Closed €80.25 (+1.5%) on Feb 27, 2026
Pharma Mar SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 7 in all · newest Mar 13, 2026 · oldest 2017
- Calls
- 2 calls with a replay · 2 with a transcript · latest Oct 27, 2023
- Decks
- 33 decks · latest September 2026
Where Pharma Mar SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| BME:PHM · Home listing | Madrid | Spain | EUR |
| gettex:PMRA | gettex | Germany | EUR |
| VIE:PHM | Vienna | Austria | EUR |
| OTC:PHMMF | OTC | United States | USD |
| LS Exchange:A2P9YT | LS Exchange | Germany | EUR |
| Tradegate:PMRA | Tradegate | Germany | EUR |
| LSIN:0RC6 | LSIN | United Kingdom | EUR |
| Lang & Schwarz:A2P9YT | Lang & Schwarz | Germany | EUR |
| Aquis:PHME · This page | Aquis | United Kingdom | EUR |
| Dusseldorf:PMRA | Dusseldorf | Germany | EUR |
| Stuttgart:PMRA | Stuttgart | Germany | EUR |
| Aquis:PHME | Aquis | United Kingdom | EUR |
| Turquoise:PHME | Turquoise | United Kingdom | EUR |
| Frankfurt:PMRA | Frankfurt | Germany | EUR |
| Hamburg:PMRA | Hamburg | Germany | EUR |
| Munich:PMRA | Munich | Germany | EUR |
Valuation
P/E 14.6× against a median of 102×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- €891.6M EUR
- P/E
- 14.6×
- EV/sales
- 3.8×
- EV/EBITDA
- 16.6×
- Price/book
- 4.2×
- Gross margin
- 90.7%
- Operating margin
- 19.1%
- Net margin
- 28.8%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pharma Mar SA · BME:PHM | US$1.10B | US$978.5M | 14.6× | 3.8× | 16.6× | 4.2× | 28.8% | 0.3× | n/a |
| CStone Pharmaceuticals · HKEX:2616 | US$1.16B | US$974.9M | n/a | 24.1× | n/a | 6.0× | −162.1% | 0.3× | n/a |
| Structure Therapeutics, Inc. · NASDAQ:GPCR | US$1.15B | −US$82.92M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.38 |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.7× | n/a | 13.4× | −216.5% | 3.8× | n/a |
| Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321 | US$1.10B | US$1.10B | 102× | 6.8× | n/a | 2.9× | 6.6% | 0.5× | n/a |
| Alpha Tau Medical Ltd · NASDAQ:DRTS | US$1.09B | US$1.00B | n/a | n/a | n/a | 55.3× | n/a | 0.8× | 1.89 |
| Kardigan, Inc. · NASDAQ:KARD | US$1.08B | US$621.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| PYC Therapeutics Limited · ASX:PYC | US$1.07B | US$775.8M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Jade Biosciences, Inc. · NASDAQ:JBIO | US$1.06B | US$583.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.14 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Median of the others | US$1.09B | US$875.4M | 102× | 18.9× | 4.4× | −145.5% | 0.3× | 1.52 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 98.94 EUR · Analysts' mean
- EPS, year to Dec 2026
- 2.08 · 6 analysts
- Revenue, year to Dec 2026
- 220.3M · 5 analysts
Team and board
| Officer | Role |
|---|---|
| Miriam Collados Gordo | Corporate Communications Manager |
| Natalia Amo | Capital Markets & Investor Relations |
| Luis Mora | Managing Director |
Events
- Next results
- Feb 25, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Pharma Mar (Madrid:PHM) Q3 2023 Earnings Call | Fri, Oct 27, 2023 | Replay |
| Pharma Mar (Madrid:PHM) Q4 2022 Earnings Call | Mon, May 01, 2023 | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | −2.5% |
| Q2 2026 | Jul 29, 2026 · After close | −1.1% |
| Q1 2026 | Apr 27, 2026 · After close | +1.9% |
| Q4 2025 | Mar 5, 2026 · After close | +0.3% |
| Q3 2025 | Oct 30, 2025 · After close | −1.4% |
| Q2 2025 | Jul 30, 2025 · After close | −0.6% |
| Q1 2025 | Apr 24, 2025 · After close | −10.3% |
| Q4 2024 | Feb 26, 2025 · After close | −0.3% |
| Q3 2024 | Oct 29, 2024 · After close | −0.1% |
| Q2 2024 | Jul 30, 2024 · After close | −0.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 23, 2024 · After close | +3.0% |
| Q4 2023 | Feb 28, 2024 · After close | −3.9% |
| Q3 2023 | Oct 26, 2023 · After close | +3.2% |
| Q2 2023 | Jul 27, 2023 · After close | −0.8% |
| Q1 2023 | Apr 27, 2023 · After close | +2.3% |
| Q4 2022 | Feb 28, 2023 · After close | −2.4% |
| Q3 2022 | Oct 26, 2022 · After close | −0.9% |
| Q2 2022 | Jul 28, 2022 · After close | −5.5% |
| Q1 2022 | Apr 28, 2022 · Before open | +0.2% |
| Q4 2021 | Feb 28, 2022 · Before open | +6.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 25 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 24 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 24 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 25 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 25 slides | May 2026 |
| Investor Presentation (November 2025) | Investor deck | 26 slides | November 2025 |
| Investor Presentation (October 2025) | Investor deck | 26 slides | October 2025 |
| Investor Presentation (July 2025) | Investor deck | 25 slides | July 2025 |
| Investor Presentation (February 2025) | Investor deck | 23 slides | February 2025 |
| Investor Presentation (April 2024) | Investor deck | 29 slides | April 2024 |
All 33 decks
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 221.4M | 174.9M | 158.2M | 196.3M | 229.8M | 270.0M | 85.8M | 162.2M | 179.3M | 180.9M |
| Cost of revenue | 12.3M | 8.18M | 9.61M | 13.6M | 16.4M | 13.7M | 5.23M | 35.9M | 45.7M | 44.0M |
| Gross profit | 209.1M | 166.7M | 148.5M | 182.7M | 213.4M | 256.2M | 80.6M | 126.3M | 133.7M | 137.0M |
| Research and development | 95.2M | 103.5M | 99.3M | 83.4M | 72.2M | 53.8M | 50.6M | 74.0M | 78.5M | 78.4M |
| Selling, general and administrative | 2.34M | 2.85M | 18.3M | 19.0M | 17.4M | 13.5M | 13.9M | 17.4M | 20.7M | 20.3M |
| Operating income | 60.7M | 6.47M | -3.83M | 44.1M | 92.4M | 155.9M | -17.5M | -14.1M | -17.7M | -18.7M |
| Depreciation and amortization | 8.02M | 6.77M | 5.76M | 5.90M | 5.58M | 7.21M | 6.05M | 6.38M | 7.06M | 7.24M |
| EBITDA | 68.7M | 13.2M | 1.93M | 50.0M | 98.0M | 163.2M | -11.4M | -7.70M | -10.6M | -11.5M |
| Interest expense | 6.51M | 8.53M | 9.43M | 11.3M | 7.68M | 3.12M | 3.89M | 4.14M | 5.12M | 5.21M |
| Income before tax | 59.7M | 12.0M | -3.62M | 43.8M | 95.1M | 145.6M | -21.7M | -18.7M | -22.9M | -24.7M |
| Income tax | -15.3M | -14.1M | -4.76M | -5.57M | 2.27M | 8.34M | -12.5M | -2.50M | 3.90M | -592.0K |
| Net income | 75.0M | 26.1M | 1.14M | 49.4M | 92.9M | 137.3M | -9.18M | -5.54M | -26.7M | -24.1M |
| Earnings per share, basic | 4.30 | 1.49 | 0.06 | 2.73 | 5.14 | 7.49 | -0.50 | -0.30 | -1.45 | -1.31 |
| Earnings per share, diluted | 4.30 | 1.49 | 0.06 | 2.73 | 5.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.8M | 63.2M | 60.0M | 149.8M | 113.3M | 96.2M | 17.6M | 22.7M | 24.1M | 14.3M |
| Short-term investments | 149.4M | 91.3M | 102.5M | 32.6M | 88.5M | 99.3M | 3.26M | 4.13M | 7.67M | 18.1M |
| Receivables | 39.4M | 34.7M | 27.6M | 29.3M | 50.9M | 26.7M | 13.2M | 23.5M | 31.4M | 62.6M |
| Inventory | 54.1M | 52.0M | 39.3M | 27.7M | 10.5M | 11.9M | 8.90M | 20.6M | 23.9M | 22.2M |
| Current assets | 283.4M | 250.2M | 252.6M | 275.2M | 295.2M | 245.7M | 50.0M | 75.1M | 93.2M | 121.0M |
| Property, plant and equipment | 57.4M | 55.9M | 43.9M | 31.2M | 27.0M | 24.7M | 25.6M | 25.5M | 30.6M | 29.0M |
| Goodwill | 0 | 2.55M | 2.55M | 2.55M | ||||||
| Total assets | 395.1M | 349.6M | 340.5M | 393.3M | 368.4M | 330.3M | 124.7M | 157.7M | 187.7M | 221.1M |
| Accounts payable | 54.3M | 51.6M | 40.3M | 30.0M | 29.3M | 21.0M | 16.5M | 31.2M | 35.8M | 36.7M |
| Current liabilities | 93.9M | 82.7M | 95.9M | 97.3M | 86.3M | 94.9M | 60.4M | 72.4M | 83.1M | 87.2M |
| Long-term debt | 35.6M | 39.9M | 27.0M | 25.9M | 33.4M | 37.7M | 53.1M | 64.9M | 73.6M | 67.6M |
| Total debt | 38.6M | 43.2M | 30.4M | 39.0M | 49.3M | 56.7M | 86.1M | 93.4M | 100.0M | 95.5M |
| Total liabilities | 143.2M | 141.3M | 147.1M | 170.3M | 190.5M | 227.5M | 117.2M | 140.2M | 164.7M | 172.6M |
| Shareholders' equity | 251.8M | 208.4M | 193.4M | 223.0M | 177.9M | 102.7M | 11.4M | 21.4M | 26.9M | 52.4M |
| Shares outstanding | 17.2M | 17.6M | 17.9M | 18.1M | 18.1M | 18.3M | 18.4M | 18.4M | 18.4M | 18.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 53.1M | 6.03M | -13.4M | 38.3M | 25.7M | 278.9M | -26.1M | -16.3M | -1.46M | -8.41M |
| Capital spending | -6.46M | -15.0M | -14.8M | -8.85M | -7.80M | -3.00M | -3.91M | -2.38M | -4.67M | -6.09M |
| Free cash flow | 46.7M | -8.99M | -28.3M | 29.5M | 17.9M | 275.9M | -30.0M | -18.7M | -6.12M | -14.5M |
| Cash from investing | -60.8M | 1.03M | -43.0M | 10.9M | 18.5M | -119.0M | 32.1M | 22.3M | 6.00M | 13.8M |
| Cash from financing | -36.5M | -5.35M | -32.1M | -13.4M | -27.4M | -73.8M | -11.0M | -7.26M | 5.26M | 1.30M |
| Dividends paid | -13.9M | -11.4M | -11.7M | -11.8M | -10.9M | -8.82M | -8.82M | -6.92M | -19.9M | -20.1M |
| Share buybacks | -34.1M | -18.6M | -37.9M | -50.2M | -40.7M | -63.7M | -7.48M | -3.45M | -6.19M | -4.17M |
| Change in cash | -45.4M | 3.21M | -89.8M | 36.5M | 17.1M | 78.6M | -5.11M | -1.34M | 9.80M | 6.66M |
Cap table
Built by 6ix from Pharma Mar SA’s releases
- Common shares
- 17,263,774
- Fully diluted
- 17,263,774
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 17,263,774 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 17,263,774 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Miriam Collados Gordo | Corporate Communications Manager · Since at least Feb 27, 2026 |
| Natalia Amo | Capital Markets & Investor Relations · Since at least Feb 27, 2026 |
Log in to ask 6ix AI your own questions about Pharma Mar SA.